|
|
||||||||
J Thorac Cardiovasc Surg 2006;131:322-328
© 2006 The American Association for Thoracic Surgery
General Thoracic Surgery |
a Thoracic Surgery Unit, Carlo Forlanini Hospital, Azienda Ospedaliera San Camillo-Forlanini, Medicine University of Rome "La Sapienza," Rome, Italy
b Department of "Studi Geoeconomici, Linguistici, Statistici, Storici per l'Analisi Regionale,", Medicine University of Rome "La Sapienza," Rome, Italy
c Department of Pneumology, S. Andrea Hospital, Medicine University of Rome "La Sapienza," Rome, Italy
Read at the Eighty-fifth Annual Meeting of The American Association for Thoracic Surgery, San Francisco, Calif, April 10-13, 2005.
Received for publication April 8, 2005; revisions received October 11, 2005; accepted for publication October 20, 2005. * Address for reprints: Giuseppe Cardillo, MD, The Thoracic Surgery Unit, Carlo Forlanini HospitalVia Portuense 332, 00149 Rome, Italy (Email: gcardillo{at}scamilloforlanini.rm.it).
| Abstract |
|---|
|
|
|---|
METHODS: From September 1995 through January 2004, a total of 861 patients (578 male, 283 female, mean age 28.6 years) underwent videothoracoscopy for recurrent and complicated primary spontaneous pneumothorax. Patients were treated with videothoracoscopic talc poudrage only (group A: Vanderschueren's stage I, 196 patients; stage II, 112 patients) or videothoracoscopic talc poudrage plus stapling of the blebs/bullae (group B: stage III, 391 patients; stage IV 162 patients). Follow-up included clinical interview and chest radiography (805 patients). In 26 patients (follow-up longer than 5 years), respiratory function was investigated to determine residual volume and diffusing lung capacity.
RESULTS: No operative deaths occurred. No patient had adult respiratory distress syndrome. Postoperative complications occurred in 29 patients (3.36%). The conversion rate to an open procedure was 0.46% (4/861). After a mean follow-up of 52.5 months, 14 patients had recurrences (1.73%). The recurrence rate was 2.41% (7/290) in group A and 1.359% (7/515) in group B (
2 value: 1.207389; P:.27; odds ratio: 0.56; 95% confidence interval: 0.20-1.62). Results of respiratory function tests were within normal ranges (80% or more of predictive value) in all 26 patients.
CONCLUSIONS: Videothoracoscopic talc poudrage achieves a high success rate in the treatment of primary spontaneous pneumothorax with a very low morbidity rate. Recurrences show a statistically significant relationship (P:.037) with smoking habits.
| Introduction |
|---|
|
|
|---|
|
Primary spontaneous pneumothorax (PSP) is a significant global problem occurring in otherwise healthy young subjects with a reported incidence of 18 to 28 cases per 100,000 population per year for men and 1.2 to 6 cases per 100,000 population per year for women.
1,2
Smoking plays a role in the development of PSP
3
: the lifetime risk in healthy smoking men may be as much as 12% compared with 0.1% in nonsmoking men.
3
PSP recurs in up to 25% of the cases after a first episode and up to 50% after a second episode, especially in the first 2 years after the initial episode.
4
Treatment options for PSP include observation, manual aspiration, intercostal tube drainage, and surgery.
1,2,4
There is clear evidence that patients with a first episode of PSP should be treated with intercostal drainage in most cases and with observation or manual aspiration in a very few selected cases. The surgical option should be offered in case of a second ipsilateral pneumothorax, first contralateral pneumothorax, bilateral spontaneous pneumothorax, spontaneous hemothorax, persistent air leak (>5-7 days of tube drainage), failure to completely re-expand after intercostal drainage, and for professions at risk (aircraft personnel, sportsmen, scuba divers).
1,2
Surgical options include open thoracotomy with bleb resection and pleurectomy or videothoracoscopy (VATS) with bleb resection plus pleural abrasion or talc pleurodesis. A recent review by Sedrakyan and associates
5
comparing only randomized trials found VATS to be associated with a shorter length of hospital stay or use of pain medication than thoracotomy, with a comparable complication profile and success rate. As regards as the method of choice for obtaining pleurodesis, most authors
6,7
prefer parietal pleurectomy or pleural abrasion, although some concern still exists with talc poudrage either because of the potential side effects of talc or because of a reported relatively high failure rate.
In this article we evaluate the short- and intermediate-term results of 861 patients treated with VATS talc poudrage for PSP in a 9-year period. A special emphasis is paid to side effects of the talc.
| Methods |
|---|
|
|
|---|
|
|
Recurrent pneumothorax is defined as a pneumothorax greater than 10% of the hemithorax in size. Twenty-six patients with no recurrences underwent pulmonary function tests to evaluate forced expiratory volume in 1 second, vital capacity, residual volume, Tiffenau index, residual volume/total lung capacity, and diffusing capacity for carbon monoxide by single breath test.
The research was approved by the Institutional Review Board of Carlo Forlanini Hospital and informed consent was obtained from each patient.
| Statistical Analysis |
|---|
|
|
|---|
2 test was used to ascertain the significance of association between two categorical variables. The unpaired Student t test was used to assess the significance between the mean of patients' age with or without recurrence of disease. The Farrington-Manning test was performed to compute the confidence intervals and hypothesis tests for the odds ratio. The overall freedom from recurrence in the two groups A and B was estimated by Kaplan-Meier survival curves and differences by the log-rank test. | Operative Technique |
|---|
|
|
|---|
| Results |
|---|
|
|
|---|
2 value1.207389; P.27; odds ratio 0.56; 95% confidence intervals 0.20-1.62). Data regarding patients passing each follow-up time point and patients lost to follow-up or having a recurrence at each time point are shown in Table 4
and Figure 1.
|
|
|
2 value 4.343785; P.037; odds ratio 0.24; 95% confidence intervals 0.06-0.93). Recurrences occurred within 12 months in 2 patients (stage IV and stage I), between 12 and 24 months in 10 patients (stage I: 3; stage II: 2; stage III: 4; stage IV: 1), and after 29 months and 38 months, respectively, in the remaining 2 patients (stage II and stage III) (Tables 4 and 5).
|
| Discussion |
|---|
|
|
|---|
In the light of our previous reported experiences
4,16
and of the results reported in the present series, we believe VATS to be an excellent technique for the treatment of recurrent and complicated PSP and talc poudrage to be the preferred tool for inducing pleurodesis (Table 5).
The overall recurrence rate reported in our series (1.73%) is much less than the 9% reported by Kennedy and Sahn
17
in a meta-analysis published in 1994. Most recent articles
4,18-23
dealing with VATS treatment of PSP have reported a lower failure rate ranging from 0% to 5% (Table 5). These results are comparable with the failure rate (0.4%-0.5%) reported with standard thoracotomy or transaxillary minithoracotomy.
20-22
There are no data to assess the optimal dosage schedule of talc. The reported dosage ranges from 2 to 10 g. There are no controlled trials to state that higher dosages of talc are more effective in inducing pleurodesis.
2
In our experience, we nebulized in the pleural cavity 2 g of talc and we believe there is no reason to use a higher dosage of talc with such technique.
4,16
With regard to the concern with the use of talc in young patients, we believe that oncologic risk can be excluded reasonably by the use of asbestos-free talc according to a survey of Chappel,
24
and coauthors. The risk of adult respiratory distress syndrome (ARDS) claimed by some authors
25
has not been confirmed in our series of 861 patients treated in a 9-year period. The risk may be related to the size of talc particles.
5
The Italian standard (length of fibers < 50 µm) seems to be a protective factor for ARDS. Empyema, never reported in our experience, may be related to technique used for the sterilization of talc.
19,26
Respiratory failure has never been observed in our series: clinical follow-up did not reveal any case of respiratory failure in the overall series of 805 patients included in the follow-up. Furthermore, pulmonary function tests were within normal ranges in a group of 26 patients with a follow-up longer than 5 years. The concern regarding the potential long-term (up to 35 years) effect of talc poudrage on a young person has been addressed by Lange, Mortenson, and Groth
27
in a group of 75 patients: they showed only a mild restrictive respiratory impairment at a follow-up of 22 to 35 years. Regarding the issue of future thoracic surgery in these patients, we believe that re-entering the chest will be a big problem either after talc poudrage or after pleurectomy/pleural abrasion. Minor postoperative complications (3.36%) were reported. Such rate appears to be much lower than the 10% complication rate reported by the largest series dealing with transaxillary minithoracothomy.
22
The reasons for such a good success rate of our technique are the great number of surgically treated patients (861 patients), as to our knowledge this experience represents the largest published series of surgically treated PSP in the world literature; the small number of surgeons (100% of the procedures were performed by 3 consultant thoracic surgeons, M.M., R.G., G.C.); the absence of a learning curve (our experience with VATS treatment of pneumothorax started much earlier); the homogeneity of the technique; and the efficacy of talc in inducing pleurodesis. The short operative time (14 ± 8 minutes) reported in the present series, not changed by additional procedures such as stapling or lysis of adhesions, represents an additional protective factor for a low complication rate. The recurrences showed a statistically significant relationship with smoking habits of the patients: 2.54% recurrence rate in smokers versus 0.598% in nonsmokers (P.037). Some authors
28,29
perform blind apical stapling in patients with no evidence of bullae (stages I and II). It is our policy to perform only pleurodesis in such patients, and our data confirm this thesis.
Recurrences after VATS talc poudrage are usually loculated and can be managed either by conservative approach or by redo VATS.
16
In conclusion, VATS talc poudrage shows a high success rate (98.27%) in the treatment of PSP with a very low morbidity rate (3.36%). Recurrences show a statistically significant relationship (P.037) with smoking habits, so that counseling regarding smoking cessation ideally should be undertaken before and after surgery.
| Discussion |
|---|
|
|
|---|
Some surgeons have continued to question the efficacy of thoracoscopy for managing patients with SPS, but I think that the results of this paper demonstrate a very low complication rate and an even lower recurrence rate that matches or exceeds any other publications on this subject. Dr Cardillo, you have given evidence that strongly supports the practice of VATS bleb resection and pleurodesis for SPS, and I would expect that this is probably a technique favored by the majority of surgeons in this room. However, your study does not alleviate my concerns regarding the potential long-term effects of talc pleurodesis on young persons with several decades of life ahead of them. You did not show any ill effects for up to 9 years after the procedure, but do you have any information on the possible natural history of talc in the pleural space over 40, 50, or 60 years? Do you have any concern that a progressive restrictive fibrothorax may develop in these patients over longer periods of follow-up? Some percentage of these patients are also likely to require thoracic surgery in the distant future. Do you have any idea what findings or difficulty to predict for a future generation of thoracic surgeons trying to resect a lung cancer in one of these patients 40 years later?
I applaud your results, but I wonder whether you might be able to achieve equivalent or very similar results with mechanical pleurodesis and avoid the theoretical complications of talc in the pleural space over several decades. You have a high-volume center. Would it be possible to conduct a randomized trial to examine the difference between pleurodesis techniques?
Dr Cardillo. Thank you, Dr Wood. We have, of course, no idea regarding the very long-term effect of talc. This is a long-term study, but maximum follow-up is 100 months, which is still not enough. The function tests we have performed in patients with a long-term follow-up over 5 years showed that this is not really a restrictive disease. We have no preoperative data. We should compare the results of the pulmonary function tests with the standard of these patients. We have done this in a small series of patients and the results were within normal range. Obviously we are concerned about long-term results. Furthermore, in a small group we have performed high-resolution computed tomography as a follow-up (not discussed it in this paper), and we have not seen any impressive change. There was a thickening of the pleural line, but it was a very small thickening. We have observed this change in some patients who were willing to undergo computed tomography.
Regarding thoracic surgery in these patients, of course it will be a big problem in the future. However, we do not have to compare these patients with normal subjects. We have to compare patients who have had talc poudrage with patients who have undergone mechanical pleurodesis, such as pleural ablation or pleurectomy. In our opinion, there is not a big difference between opening the chest in a patient who underwent pleural ablation (and that means bleeding) or in a patient who underwent pleurectomy or talc poudrage.
Dr Allen. Could you do a randomized trial?
Dr Cardillo. That would be a good idea. However, if one compares the different techniques of pleurodesis up until now, the results in the literature seems to indicate that talc poudrage is preferable. Of course, if possible, a randomized study would be optimal.
Dr Carlos Saldarriaga (Medellin, Colombia). There were 283 women in your study. How many patients with catamenial pneumothorax or diaphragmatic pleural syndrome did you have in your series and how did you treat these patients?
Dr Cardillo. Catamenial pneumothorax has been occasionally found in our series. In these patients you have to carefully evaluate the diaphragm, looking for some endometrial tissue. Really, I think we have included only one or two patients with catamenial pneumothorax, but in our series we have not found in any patient endometrial tissue along the diaphragm or along the pleura.
Dr Malcolm M. DeCamp (Boston, Mass). I enjoyed your report very much. It is certainly a tremendous large-volume series that sort of dwarfs the other reports by threefold or fourfold.
I have two questions, the first pertaining to indications for the patients with persistent air leak. How long is persistent? How many days will you wait for an air leak to resolve before you would suggest surgery? Second, would you elaborate on the postoperative management? You said it was your practice in this retrospective series to leave the chest tubes for 4 or 5 days. What are the criteria now other than resolution of air leak before you will remove the chest tube?
Dr Cardillo. In our opinion, a leak persisting for 4 to 5 days is a long-term air leak. When we started our experience, we decided to wait at least 5 days before doing the operation in patients with an SPS, but with time we are changing our minds. Now we wait 4 and, in some cases, 2 days before doing the operation. If the lung is well inflated, then we can wait a little longer, but if the lung is not well inflated, even after 2 days, I think it is time for surgery.
Regarding the removal time, in accordance with a study of Dr Boutin, in the beginning we decided to leave the tube in place at least 5 days, even if the lung was well inflated and there was no air leak. Now I think we wait 4 days, but not less than 4 days. This is our rule.
Dr Walter Weder (Zurich, Switzerland). You did not mention as a possible concern that these talc fibers are found in all organsin the brain, in the heart, in the muscle, in the kidneyand this has been shown in animal studies and in autopsies also. Is this not a concern for you? Do you inform these patients that these fibers go to all organs?
Dr Cardillo. Thank you, Dr Weder. Talc embolization was described by Dr West either in animals or in human beings in a recent paper that I cited in my presentation. Dr West published in the Current Opinion in Pulmonary Medicine in 2004 a paper regarding the issue of systemic embolization of talc. He works at the Oxford Pleural Diseases Unit in the United Kingdom, and he has a great experience: in his paper he wrote that the problem of systemic embolization is not yet clarified. So we do not know the ramifications. This problem may even be related to the diameter of the talc particles. When we have the results of the ongoing trial on the safety of talc, we will have more data to address this issue.
Dr David Waller (Leicester, United Kingdom). Dr Cardillo, you have shown that pleurectomy may not be needed to treat this condition. You have also shown that a third of the patients do not need resection of the blebs. What is your opinion of the treatment of this condition by pulmonologists by the so-called medical thoracoscopy?
Dr Cardillo. Thank you, Dr Waller.
In my country we do not let pulmonologists treat pneumothorax. Only thoracic surgeons are allowed to do thoracoscopy. I work in a hospital in which there are many pulmonologists. They do bronchoscopy, they do pleuroscopy, but we absolutely do not let them to do thoracoscopy. So we are the only doctors treating pneumothorax in my hospital. I do not know about other institutions.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
O. Rena, F. Massera, E. Papalia, C. Della Pona, M. Robustellini, and C. Casadio Surgical pleurodesis for Vanderschueren's stage III primary spontaneous pneumothorax Eur. Respir. J., April 1, 2008; 31(4): 837 - 841. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Alifano, C. Jablonski, H. Kadiri, P. Falcoz, A. Gompel, S. Camilleri-Broet, and J.-F. Regnard Catamenial and Noncatamenial, Endometriosis-related or Nonendometriosis-related Pneumothorax Referred for Surgery Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 1048 - 1053. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P Currie, R. Alluri, G. L Christie, and J. S Legge Pneumothorax: an update Postgrad. Med. J., July 1, 2007; 83(981): 461 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Marcheix, L. Brouchet, C. Renaud, Y. Lamarche, A. Mugniot, V. Benouaich, J. Berjaud, and M. Dahan Videothoracoscopic silver nitrate pleurodesis for primary spontaneous pneumothorax: an alternative to pleurectomy and pleural abrasion? Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1106 - 1109. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cardillo, F. Carleo, L. Carbone, M. Di Martino, L. Salvadori, A. Ricci, L. Petrella, and M. Martelli Long-term lung function following videothoracoscopic talc poudrage for primary spontaneous recurrent pneumothorax Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 802 - 805. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Noppen Who's (still) afraid of talc? Eur. Respir. J., April 1, 2007; 29(4): 619 - 621. [Full Text] [PDF] |
||||
![]() |
I. Hunt, B. Barber, R. Southon, and T. Treasure Is talc pleurodesis safe for young patients following primary spontaneous pneumothorax? Interactive CardioVascular and Thoracic Surgery, February 1, 2007; 6(1): 117 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Aelony and J. P. Janssen Video-assisted Thoracic Surgery versus Medical Thoracoscopic Talc Poudrage in Spontaneous Pneumothorax. Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 103 - 103. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |